CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM...
Early Phase 1
New York, New York, United States and 4 other locations
efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...
Phase 1, Phase 2
New York, New York, United States and 20 other locations
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)...
Phase 1, Phase 2
New York, New York, United States and 6 other locations
(MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields).The stud...
Phase 1
Bronx, New York, United States of America
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....
Phase 2, Phase 3
New York, New York, United States and 61 other locations
therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after sur...
Phase 2, Phase 3
Pennington, New Jersey, United States and 7 other locations
with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.The names of the study drugs involved in this study are:* N...
Phase 1
New York, New York, United States and 3 other locations
The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the...
New York, New York, United States
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...
Phase 2
New York, New York, United States and 80 other locations
as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma...
Phase 1
New York, New York, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal